Medicare Enrolled
Dr. John Scagnelli, M.D.
Neurology · Raleigh, NC
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Scagnelli from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Scagnelli?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Scagnelli
Dr. John Scagnelli is a neurology specialist in Raleigh, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Scagnelli performed 45,529 Medicare services across 989 unique beneficiaries.
Between the years covered by Open Payments, Dr. Scagnelli received a total of $404,200 from 71 pharmaceutical and/or device companies across 1772 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Scagnelli is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in NC
$404,200 industry payments
Medicare Practice Summary
Medicare Utilization ↗45,529
Medicare services
Top 2% in NC for neurology
989
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,396 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, natalizumab, 1 mg | 17,100 | $19 | $35 |
| Ocrelizumab infusion (Ocrevus) for MS | 12,900 | $19 | $110 |
| MRI contrast dye injection (gadobutrol) | 9,610 | $0 | $2 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 4,500 | $38 | $90 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
367 | $4 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
206 | $80 | $220 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
167 | $109 | $380 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
107 | $123 | $300 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
105 | $46 | $228 |
| MRI of brain with and without contrast An MRI scan of the brain using contrast dye both before and after administration to provide detailed images of brain structures. |
99 | $147 | $2,235 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
92 | $90 | $510 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
79 | $57 | $150 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
62 | $16 | $166 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
35 | $10 | $100 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
31 | $15 | $166 |
| MRI scan of brain, without contrast A magnetic resonance imaging test of the brain that does not use contrast dye. This procedure creates detailed images of the brain's structure using magnetic fields and radio waves. |
30 | $87 | $1,980 |
| MRI of upper spine with contrast An MRI scan of the upper spinal canal using a contrast dye to enhance the images. The contrast helps provide a clearer view of the spinal structures. |
27 | $73 | $1,746 |
| MRI of upper spine without contrast An MRI scan of the upper spinal canal that does not use contrast dye. This imaging test uses magnetic fields and radio waves to create detailed pictures of the spine. |
12 | $68 | $1,518 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.9% high complexity
69.9% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$404,200
Total received (2018-2024)
Avg $57,743/year across 7 years
Top 1% in NC for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
71
Companies
1,772
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$324,147 (80.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$68,652 (17.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,401 (2.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$57,406
2023
$49,095
2022
$47,927
2021
$58,425
2020
$38,803
2019
$118,430
2018
$34,113
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TG Therapeutics, Inc.
$25,802
Biogen, Inc.
$11,551
Genentech USA, Inc.
$8,827
Amgen Inc.
$7,177
Alexion Pharmaceuticals, Inc.
$688
EMD Serono, Inc.
$470
Celgene Corporation
$407
Novartis Pharmaceuticals Corporation
$334
Mallinckrodt Hospital Products Inc.
$229
ABBVIE INC.
$224
Lilly USA, LLC
$205
UCB, Inc.
$192
ANI Pharmaceuticals, Inc.
$172
CSL Behring
$152
PFIZER INC.
$141
ARGENX US, INC.
$122
BANNER LIFE SCIENCES, LLC
$101
Merz Pharmaceuticals, LLC
$98
Vanda Pharmaceuticals Inc.
$85
Neurocrine Biosciences, Inc.
$78
Avadel CNS Pharmaceuticals, LLC
$37
Takeda Pharmaceuticals U.S.A., Inc.
$33
ACADIA Pharmaceuticals Inc
$32
JAZZ PHARMACEUTICALS INC.
$32
MDD US Operations, LLC
$25
Genentech, Inc.
$22
Otsuka America Pharmaceutical, Inc.
$21
GENZYME CORPORATION
$21
Acorda Therapeutics, Inc
$20
Axsome Therapeutics, Inc.
$19
Kedrion Biopharma, Inc.
$19
HARMONY BIOSCIENCES LLC
$19
Ipsen Biopharmaceuticals, Inc
$19
Neurelis, Inc.
$17
Amneal Pharmaceuticals LLC
$15
Top 3 companies account for 80.4% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$99,520
Biogen, Inc.
$92,351
Genentech USA, Inc.
$58,609
Alexion Pharmaceuticals, Inc.
$32,155
EMD Serono, Inc.
$27,402
TG Therapeutics, Inc.
$25,802
Novartis Pharmaceuticals Corporation
$22,019
Horizon Therapeutics plc
$13,897
Amgen Inc.
$7,507
TG THERAPEUTICS, INC.
$4,873
Celgene Corporation
$4,105
CYCLE PHARMACEUTICALS INC
$3,160
Genentech, Inc.
$2,266
NOVARTIS PHARMACEUTICALS CORPORATION
$1,650
BANNER LIFE SCIENCES, LLC
$1,183
Mallinckrodt Hospital Products Inc.
$605
Supernus Pharmaceuticals, Inc.
$556
UCB, Inc.
$499
CSL Behring
$444
ABBVIE INC.
$439
Lilly USA, LLC
$407
AbbVie Inc.
$388
PFIZER INC.
$306
ARGENX US, INC.
$293
Janssen Pharmaceuticals, Inc
$266
ANI Pharmaceuticals, Inc.
$250
Teva Pharmaceuticals USA, Inc.
$229
JAZZ PHARMACEUTICALS INC.
$202
Axsome Therapeutics, Inc.
$199
Acorda Therapeutics, Inc
$194
Lundbeck LLC
$145
SANOFI-AVENTIS U.S. LLC
$142
Grifols USA, LLC
$136
Merz Pharmaceuticals, LLC
$121
Biohaven Pharmaceutical Holding Company Ltd.
$118
Allergan Inc.
$116
Avion Pharmaceuticals
$112
ARBOR PHARMACEUTICALS, INC.
$110
Neurocrine Biosciences, Inc.
$93
Vanda Pharmaceuticals Inc.
$85
ACADIA Pharmaceuticals Inc
$83
Mitsubishi Tanabe Pharma America, Inc.
$83
Otsuka America Pharmaceutical, Inc.
$78
Exeltis, USA Inc.
$72
Takeda Pharmaceuticals U.S.A., Inc.
$65
Adamas Pharmaceuticals, Inc.
$61
GE HEALTHCARE
$54
Avanir Pharmaceuticals, Inc.
$51
SK Life Science, Inc.
$49
Mallinckrodt Enterprises LLC
$46
HARMONY BIOSCIENCES LLC
$46
Merz North America, Inc.
$42
Banner Life Sciences, LLC
$41
MDD US Operations, LLC
$41
Ipsen Biopharmaceuticals, Inc
$39
Avadel CNS Pharmaceuticals, LLC
$37
Sunovion Pharmaceuticals Inc.
$35
Collegium Pharmaceutical, Inc.
$35
Neurelis, Inc.
$34
Amneal Pharmaceuticals LLC
$31
Allergan, Inc.
$29
Mallinckrodt LLC
$29
ASSERTIO THERAPEUTICS, Inc.
$27
GE HealthCare
$25
Arbor Pharmaceuticals, Inc.
$25
Kedrion Biopharma, Inc.
$19
AstraZeneca Pharmaceuticals LP
$16
E.R. Squibb & Sons, L.L.C.
$16
Bayer HealthCare Pharmaceuticals Inc.
$13
Zyla Life Sciences
$12
Boston Scientific Corporation
$11
Top 3 companies account for 62.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · Aimovig · Albuked · Austedo XR · BAFIERTAM · BOTOX · BOTOX - NEUROLOGY · BOTOX THERAPEUTIC · BRIUMVI · Betaseron · Briviact · COMIRNATY · COPAXONE · Cimzia · Dhivy · Dysport · ELYXYB - celecoxib · EMGALITY · EPIDIOLEX · EVUSHELD · Enspryng · FABRAZYME · GENERAL DBS · GILENYA · GOCOVRI · Gamunex-C · Gocovri · Gralise · HYQVIA · Hizentra · Horizant · INBRIJA · INGREZZA · KESIMPTA · LEMTRADA · LUMRYZ · LYVISPAH · MAVENCLAD · MAYZENT · Mavenclad · NITYR · NORTHERA · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OXTELLAR XR · Ocrevus · Ocrevus Zunovo · Ongentys · Ozanimod · PANZYGA · PAXLOVID · PONVORY · PURIFIED CORTROPHIN GEL · Ponvory · QULIPTA · RYTARY · Radicava · Rebif · Rystiggo · SOLIRIS · SPRIX · SUNOSI · Soliris · Sunosi · TECFIDERA · TEPEZZA · TROKENDI XR · TYSABRI · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · WAKIX · Wakix · XEOMIN · XYWAV · Xeomin · ZEPOSIA · Zilbrysq · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (80%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for neurology in NC.
Geographic Context
Neurologists within 10 mi
115
Per 100K population
10.0
County median income
$101,763
Nearest hospital
REX HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Scagnelli is a mixed practice specialist, with above-average Medicare volume (top 2% in NC), with speaking/promotional industry engagement in the top 1% of NC peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Scagnelli experienced with injection, natalizumab, 1 mg?
Based on Medicare claims data, Dr. Scagnelli performed 17,100 injection, natalizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Scagnelli receive payments from pharmaceutical companies?
Yes. Dr. Scagnelli received a total of $404,200 from 71 companies across 1,772 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Scagnelli's costs compare to other neurologists in Raleigh?
Dr. Scagnelli's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Scagnelli) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Raleigh
Browse neurologists in Raleigh ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in NC
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in NC
Which NC neurologists receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology